Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration (FDA) for their...
By Ankika Biswas and Bansari Mayur Kamdar (Reuters) -European shares rose on Friday, boosted by financials and healthcare, ending the week higher on growing optimism that central...
(Reuters) - Drugmaker Sanofi (EPA:SASY) is working with Rothschild & Co on a separate listing of the consumer health division, which could be valued at more than $20 billion in...
PARIS (Reuters) -French financial prosecutors have opened a preliminary probe into drugmaker Sanofi (EPA:SASY) over possible share price manipulation, a person close to the...
New York, USA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing...
Will eventually do well because of French strategy. France is at the top table and Sanofi was made up by absorbing others to grow. Look at 20% in a couple of years